Dr. Hudis Discusses Obesity as a Modifiable Risk Factor

Clifford A. Hudis, MD
Published: Tuesday, Aug 06, 2013

Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center, discusses obesity as a modifiable risk factor for cancer.

As president-elect, Hudis says that ASCO will begin to tackle the growing problem of obesity and its relationship to several common tumors: breast, high-grade prostate, colon, non-Hodgkin lymphoma, and others. There is a substantial amount of evidence that obesity is associated with higher rates of these tumors and worse outcomes.

Hudis says that ASCO has the opportunity to explore the science behind this issue and translate it into action. The theme for his term as president relates to this: the obligation to help society confront obesity as a modifiable risk factor. It is now projected in the U.S. that obesity will replace tobacco as the leading modifiable risk factor for these cancers.

Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center, discusses obesity as a modifiable risk factor for cancer.

As president-elect, Hudis says that ASCO will begin to tackle the growing problem of obesity and its relationship to several common tumors: breast, high-grade prostate, colon, non-Hodgkin lymphoma, and others. There is a substantial amount of evidence that obesity is associated with higher rates of these tumors and worse outcomes.

Hudis says that ASCO has the opportunity to explore the science behind this issue and translate it into action. The theme for his term as president relates to this: the obligation to help society confront obesity as a modifiable risk factor. It is now projected in the U.S. that obesity will replace tobacco as the leading modifiable risk factor for these cancers.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x